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Research
AbstrACt
background Cervical cancer is the leading cause of 
cancer death for women in Uganda, despite the potential 
for prevention through organised screening. Community-
based self-collected human papillomavirus (HPV) testing 
has been proposed to reduce barriers to screening.
Objective Our objective was to evaluate the cost-
effectiveness of the Advances in Screening and Prevention 
of Reproductive Cancers (ASPIRE) trial, conducted in 
Kisenyi, Uganda in April 2014 (n=500). The trial compared 
screening uptake and compliance with follow-up in two 
arms: (1) community-based (ie, home or workplace) self-
collected HPV testing (facilitated by community health 
workers) with clinic-based visual inspection with acetic 
acid (VIA) triage of HPV-positive women (‘HPV-VIA’) and (2) 
clinic-based VIA (‘VIA’). In both arms, VIA was performed at 
the local health unit by midwives with VIA-positive women 
receiving immediate treatment with cryotherapy.
Design We informed a Monte Carlo simulation model of 
HPV infection and cervical cancer with screening uptake, 
compliance and retrospective cost data from the ASPIRE 
trial; additional cost, test performance and treatment 
effectiveness data were drawn from observational studies. 
The model was used to assess the cost-effectiveness of 
each arm of ASPIRE, as well as an HPV screen-and-treat 
strategy (‘HPV-ST’) involving community-based self-
collected HPV testing followed by treatment for all HPV-
positive women at the clinic.
Outcome measures The primary outcomes were 
reductions in cervical cancer risk and incremental cost-
effectiveness ratios (ICERs), expressed in dollars per year 
of life saved (YLS).
results HPV-ST was the most effective and cost-effective 
screening strategy, reducing the lifetime absolute risk of 
cervical cancer from 4.2% (range: 3.8%–4.7%) to 3.5% 
(range: 3.2%–4%), 2.8% (range: 2.4%–3.1%) and 2.4% 
(range: 2.1%–2.7%) with ICERs of US$130 (US$110–
US$150) per YLS, US$240 (US$210–US$280) per YLS, and 
US$470 (US$410–US$550) per YLS when performed one, 
three and five times per lifetime, respectively. Findings 
were robust across sensitivity analyses, unless HPV costs 
were more than quadrupled.
Conclusions Community-based self-collected HPV testing 
followed by treatment for HPV-positive women has the 
potential to be an effective and cost-effective screening 
strategy.
IntrODuCtIOn 
High-income countries have significantly 
reduced cervical cancer incidence and 
mortality by implementing organised cytolo-
gy-based screening programmes.1 The intro-
duction of the prophylactic HPV vaccine has 
the potential to further reduce incidence and 
mortality of cervical and other HPV-related 
cancers. Despite these advances, cervical 
cancer remains a major cause of morbidity 
and mortality in low- and middle-income 
countries (LMICs) due to the absence of 
effective, organised screening programmes. 
In Uganda, cervical cancer is the top cause 
of cancer death in women.2 In 2012, Uganda 
introduced a publicly funded national 
HPV vaccination programme in parts of 
the country.3 However, due to low vaccine 
coverage and the targeting of adolescent girls 
strengths and limitations of this study
 ► To the best of our knowledge, this is the first study 
to leverage randomised trial data to evaluate the 
cost-effectiveness of community-based self-collect-
ed HPV testing that is performed at women’s homes 
or places of work.
 ► The use of community health workers has the po-
tential to reduce demands on overburdened health-
care providers.
 ► Costs of the Advances in Screening and Prevention 
of Reproductive Cancers trial are retrospective as 
the trial was not designed to evaluate cost-effective-
ness. Therefore, costs may reflect study as opposed 
to real-world conditions.
 ► We also did not consider human resource and ca-
pacity constraints in the Ugandan healthcare system.
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before sexual debut,3 screening continues to be the only 
form of prevention for most women.
There are significant barriers to access, implementa-
tion and quality assurance for cytology-based screening in 
LMICs. A systematic review of cost-effectiveness analyses 
in LMICs found that cytology is not an efficient screening 
test in low-resource settings.4 The WHO no longer recom-
mends cytology-based screening in LMICs that have not 
already achieved high coverage and quality assurance.5 
Instead, visual inspection with acetic acid (VIA) and HPV 
DNA testing have been proposed as alternatives that may 
be better suited to low-income settings. While VIA is inex-
pensive, provides same-visit results and allows for imme-
diate treatment, test performance varies widely across 
providers, populations and settings.6 Currently, WHO 
recommends HPV testing if resources permit.5 HPV testing 
can be administered using provider-collected or self-col-
lected sampling. While provider collection (of cervical 
samples) has been demonstrated to have higher sensitivity 
to detect precancer,6 self-collection (of vaginal samples) has 
been shown to reduce patient barriers to screening7 and 
may increase effectiveness and cost-effectiveness when it 
increases population coverage.4 8
While several studies have evaluated the cost-effective-
ness of self-collected HPV testing in LMICs,4 9 10 we could 
not identify any that evaluate the cost-effectiveness of a 
delivery model where self-collected HPV tests are offered 
at women’s homes and/or places of work. In addition, we 
could not identify any studies that leveraged randomised 
trial data to test the hypothesis that the increased uptake 
associated with self-collection is cost-effective relative 
to clinic-based screening. Therefore, our objective with 
this study was to evaluate the cost-effectiveness of a 
randomised trial run by the Advances in Screening and 
Prevention of Reproductive Cancers (ASPIRE) Project, 
which compared community-based self-collected HPV 
testing to clinic-based VIA in Uganda.11
MethODs
Analytical framework
We used a previously developed Monte Carlo simulation 
model of HPV infection and cervical cancer that was cali-
brated to epidemiological data from Uganda10 12 13 to 
project the lifetime health and economic outcomes asso-
ciated with self-collected HPV testing versus clinic-based 
VIA. The model was informed by screening uptake, 
follow-up and retrospective costing data from the ASPIRE 
trial, conducted in Kisenyi, Uganda.11
The primary outcomes were the incremental cost-ef-
fectiveness ratio (ICER) and per cent reduction in life-
time cervical cancer risk (ie, cumulative lifetime cervical 
cancer incidence). ICERs are defined as the marginal cost 
(discounted per women cost) divided by the marginal 
benefit (discounted life expectancy) of a screening 
strategy compared with the next most costly strategy, after 
eliminating strategies that are dominated (defined as 
either more costly and less effective or having a higher 
ICER than more effective strategies). ICERs are expressed 
in 2014 US$ per year of life saved ($/YLS). We consid-
ered screening strategies with an ICER below US$730,14 
the GDP per capita of Uganda in 2014, to be very cost-ef-
fective.15 In keeping with guidelines on cost-effectiveness 
analysis, we discounted all costs and future life years at a 
rate of 3% per year and evaluated costs from a societal 
perspective, including costs irrespective of the payer.16
the AsPIre trial
The ASPIRE trial was conducted in the Kisenyi district 
of Kampala, Uganda. For the trial, community health 
workers (CHWs) recruited 500 women at their homes 
or places of work who were between the ages of 30 and 
65, lived and/or worked in Kisenyi, and had access to a 
mobile phone.11 At the time of enrolment, consenting 
women were randomised into either HPV self-collection 
with VIA triage for HPV-positive women (‘HPV-VIA’) 
or VIA screen and treat (‘VIA’). Women randomised to 
the HPV-VIA arm received instructions from a CHW on 
self-collection and were given the opportunity to self-col-
lect HPV, Neisseria gonorrhoea and Chlamydia trachomatis 
(NGCT) samples. CHWs would then transport the samples 
to local laboratories in Kampala, Uganda where they were 
tested for HPV and NGCT. The CHWs contacted women 
by phone with their results. If HPV-positive, women were 
scheduled for a VIA triage test by a midwife at Kisenyi 
Health Unit. If VIA-positive, the women were offered 
immediate cryotherapy (if eligible for cryotherapy) or 
sent to a tertiary care centre for further diagnosis and 
treatment (if ineligible for cryotherapy for reasons such 
as lesion size, inability to adequately visualise the cervix or 
suspicion of cancer).
Women randomised to the VIA arm were scheduled for 
an appointment at the Kisenyi health unit. The CHWs 
contacted women in this arm by phone to remind them 
of their VIA appointment. When the VIA was performed, 
women were also offered provider-collected NGCT 
testing. Like the HPV-VIA arm, women who had a posi-
tive VIA screen were offered immediate cryotherapy (if 
eligible) or referred to a tertiary care centre for further 
evaluation and treatment.
Mathematical simulation model
The individual-based microsimulation model of cervical 
cancer has been previously described, but we summarise 
key features here.10 12 13 The model was programmed in 
C++. Girls enter the model at age 9, and each month face 
probabilities of transitioning between mutually exclu-
sive health states including HPV infection (stratified by 
HPV genotype), cervical intraepithelial neoplasia grade 2 
(CIN2), CIN3, cervical cancer (local, regional or distant 
stage) and death (figure 1). Transitions between health 
states may be determined by age, HPV type, duration 
of HPV infection, duration of CIN, history of previous 
infection and patterns of screening and treatment of 
precancer. Each month, death can occur from cervical 
cancer or non-cervical cancer causes (ie, background 
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mortality). Disease progression and regression, clinical 
events, and economic outcomes are tracked over the life-
time of each woman and aggregated over the cohort of 
one million women.
We used a likelihood-based approach (described in 
detail elsewhere) to calibrate the natural history model 
to epidemiological data from Uganda.10 12 Data on HPV 
incidence,17 progression and clearance,18 precancer 
progression19 and regression,20 and cancer progres-
sion and mortality21–24 from longitudinal studies were 
used to establish baseline input values. Age-specific and 
type-specific HPV incidence, naturally acquired immunity 
following HPV infection, and progression and regression 
of precancer were identified as parameters with a high 
degree of uncertainty, and were thus selected for calibra-
tion. We set a range of plausible bounds for these uncer-
tain model parameters and then randomly sampled from 
a uniform distribution across this range of values.10 12 The 
range of plausible bounds that was sampled from for each 
variable is shown in the technical online supplementary 
appendix. Each model simulation selected one random 
value within the bounds for each uncertain param-
eter, creating a unique natural history input parameter 
set. By summing the log-likelihood of model-projected 
outcomes for each input parameter set relative to the 
epidemiological data on age-specific high-risk HPV prev-
alence and age-specific cancer incidence from Uganda,10 
we computed a goodness-of-fit score. We selected the 50 
top-fitting input parameter sets to use in this analysis. 
Results are reported as the mean and range across the top 
50 parameter sets, and ICERs are reported as the ratio of 
the mean costs divided by the mean effects of one strategy 
versus another across sets.25
screening strategies
We considered the following screening strategies 
(figure 2): (1) self-collected HPV testing at home or work 
followed by VIA triage for HPV-positive women, with cryo-
therapy for eligible women who were positive on both 
tests (HPV-VIA); (2) self-collected HPV testing at home 
or work followed by cryotherapy for all eligible HPV-pos-
itive women (HPV screen-and-treat strategy, HPV-ST) 
and (3) VIA at the clinic followed by cryotherapy for 
eligible women (VIA). While HPV-ST was not evaluated 
in the ASPIRE study, we considered this strategy over 
concerns that VIA triage of HPV-positive women may 
miss some precancer. The HPV-ST strategy is identical to 
the HPV-VIA strategy, except we assumed that all eligible 
HPV-positive women were referred to cryotherapy at 
Kisenyi clinic (regardless of visual inspection findings). In 
all three strategies, women who were not deemed eligible 
for cryotherapy at the Kisenyi clinic (based on visual 
inspection in all strategies) were referred to a tertiary 
care centre for further evaluation with colposcopy.
We evaluated screening once in a lifetime at age 39 to 
represent the average age and number of screens in the 
ASPIRE trial. In keeping with WHO guidelines to priori-
tise screening among women aged 30–49 years,5 we also 
evaluated scenarios of screening three times at ages 30, 
40 and 50 years and screening every 5 years at ages 30, 35, 
40, 45 and 50 years. For the base case analysis, we assumed 
screening coverage of 70%. Table 1 displays model inputs 
on screening uptake, compliance, test performance, 
treatment eligibility and treatment effectiveness. Values 
for screening uptake, the proportion of women who were 
reachable by phone for delivery of results, and compli-
ance with Kisenyi Health Centre visits and cryotherapy 
Figure 1 Model schematic. Screening, diagnosis and treatment of precancer or cancer are determined by screening 
strategy (this figure has been reproduced by permission of Oxford University Press, https://global.oup.com/academic/rights/
permissions/autperm/?cc=us&lang=en&). CIN2, cervical intraepithelial neoplasia grade 2; CIN3, cervical intraepithelial neoplasia 
grade 3.
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were informed by the ASPIRE trial. Compliance and 
uptake for the HPV-ST strategy was assumed to be iden-
tical to the HPV-VIA arm as the structure of the screening 
pathway was assumed to be the same. HPV test perfor-
mance characteristics with self-collection were informed 
by a care HPV demonstration project in Uganda.6
Cost data
Cost data and time estimates are described extensively 
in the technical online supplementary appendix and 
presented in table 1. Costing was done from a societal 
perspective so that policy-makers can evaluate the impact 
on all stakeholders.26 Costs included direct medical costs 
(including CHW salary, provider wages, supply costs, 
sample transport costs, laboratory costs and equipment 
costs), women’s time costs and programmatic costs. 
Briefly, cost data and time estimates were derived from a 
review of ASPIRE budget sheets, receipts, grant reconcil-
iation sheets and consultation with researchers involved 
in the trial. When applicable, costs attributable to NGCT 
sampling were excluded. In several cases, ASPIRE cost 
data were not available and we instead used costs from 
other studies. HPV self-collection test cost, supplies, 
HPV laboratory costs and cryotherapy equipment costs 
were informed by the PATH START-UP demonstration 
project in Uganda.6 9 Cancer treatment costs were derived 
from Campos et al.27 Costs were collected in US$, Cana-
dian dollars and Ugandan shillings (UGX). All costs are 
presented in 2014 US$. If costs were collected in 2014, 
exchange rates were applied to convert costs to 2014 US$.28 
If costs were collected in a different year, we converted 
the currency to UGX, applied Ugandan GDP deflators 
to account for inflation,29 and then converted the cost to 
Figure 2 Pathways of care. This figure depicts the HPV-VIA and VIA screening strategies. The HPV-ST strategy is identical 
to HPV-VIA, except all HPV-positive women are offered cryotherapy (if eligible) or are referred to a tertiary care centre (if 
ineligible). ST, screen-and-treat strategy; VIA, visual inspection with acetic acid.
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Table 1 Baseline values and ranges for sensitivity analysis*
Baseline value Sensitivity analysis
Screening and treatment parameters
Screening age(s)5 11 1x: age 39 years;
3x: ages 30, 40 and 50 years;
5x: ages 30, 35, 40,45 and 50 years
–
Population coverage 70.0% 40.0%–100%
Uptake of self-collected HPV testing11 99.2% – 
Uptake of VIA11 48.4% – 
Proportion of women successfully contacted over phone with 
HPV test results11
63.0% 46.6%–90.0%
Proportion of contacted HPV-positive women attending the 
clinic11
97.1% – 
Compliance for all other visits 85.0% 0%; 40.0%
Proportion of eligible women receiving cryotherapy following 
positive VIA11
78.6% – 
Proportion of eligible women receiving cryotherapy following 
positive HPV test11
78.6% – 
Proportion of women receiving treatment following 
colposcopy
85.0%
Proportion of women who refuse cryotherapy then return at a 
later date11 37
0.0% 52.0%
Test sensitivity/specificity for CIN2+
  HPV (self-collected)6 77.0%/82.0% 100%/100%
  VIA (primary screen)6 31 73.6%/66.6% 41.4%/94.5%
  VIA (triage test)6 32 33 73.6%/66.6% 36.4%–81.9%/
66.6%–94.5%
Test sensitivity/specificity for CIN1+, colposcopy10‡ 95.0%/51.0% – 
Eligibility for cryotherapy34–36
  No lesion 90.0% 72.2%–92.7%
  CIN2 85.0% 42.2%–87.7%
  CIN3 75.0% 42.2%–82.7%
  Cancer 10.0% – 
Cryotherapy effectiveness at the clinic38 44 81.0% 70.0%–92.0%
Cryotherapy effectiveness at the referral centre44 81.0% 70.0%–92.0 % 
Proportion of women who retain HPV infection following 
cryotherapy
10.0% – 
Cost parameters, women’s time costs
  Women’s time cost, per hour30 US$0.46 – 
  Self-collection of HPV sample US$0.19 – 
  VIA screen US$1.38 – 
  Cryotherapy with no VIA (Kisenyi) US$1.46
  Extra time for cryotherapy post-VIA US$0.03 – 
  Colposcopy and biopsy US$2.76 – 
  Cryotherapy (Mulago National Referral Hospital) US$2.76 – 
Cost parameters, programmatic costs†
  Programmatic cost per women screened US$6.58 – 
Cost parameters, direct medical costs§
  Self-collected HPV test10 11 45 US$12.73 US$34.08
Continued
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US$. Equipment costs were annualised to represent the 
duration of their use assuming a 3% interest rate.
Women’s time spent travelling, waiting for and 
receiving care was valued using an average hourly wage 
for women enrolled in the trial. This was calculated by 
applying ASPIRE demographic survey data on education 
levels to Ugandan Ministry of Gender, Labour and Social 
Development data on average wages based on education 
level.30 Time estimates were informed by the ASPIRE 
demographic survey and consultation with researchers 
and clinicians who took part in the ASPIRE trial. Other 
societal costs, such as lost future productivity and impact 
on education have not been included due to a lack of 
data to objectively estimate these costs.
Programmatic costs were derived from the ASPIRE 
trial. These costs included a programme assistant and a 
community preparedness campaign that occurred in the 
month leading up to the trial to educate women on HPV 
and cervical cancer.
Further details on cost data and assumptions are 
provided in the technical online supplementary appendix.
sensitivity and scenario analyses
To explore uncertainty around model inputs, we 
performed univariate and multivariate sensitivity analyses 
under the scenario of once in a lifetime screening at age 
39 on the following variables: VIA primary screening test 
sensitivity/specificity,31 VIA triage test sensitivity,32 33 cryo-
therapy eligibility,11 34–36 HPV test direct medical costs,11 
cryotherapy treatment costs,11 cancer treatment costs,37 
cryotherapy efficacy,38 the proportion of women who 
were reachable by phone for results delivery,11 midwife 
costs per VIA, CHW costs, loss to follow-up for referral 
centre visits, screening coverage, proportion of women 
who return for cryotherapy after initially refusing, colpos-
copy costs and discount rates.
Additionally, we performed the following scenario anal-
yses: we evaluated only HPV-VIA and VIA once, three times, 
and five times per lifetime, ignoring the HPV-ST strategy 
that was inferred from ASPIRE results; we assumed all 
precancer treatment at referral centres was loop electro-
surgical excisional procedure (LEEP) by increasing the 
treatment efficacy to 96.4%39 and the direct medical costs 
to US$86.70 per LEEP (in the base case, only cryotherapy 
was available)9; and we leveraged data from a study demon-
strating that door-to-door follow-up with CHWs in South 
Africa increased adherence to cervical cancer screening 
visits and increased the CHW cost per women by US$2.68 
to increase compliance in all three strategies.40
results
reduction in cervical cancer risk
The relative and absolute reductions in cancer risk for 
HPV-ST, HPV-VIA and VIA once per lifetime, three times 
per lifetime and five times per lifetime compared with 
no screening are presented in table 2. At every screening 
frequency, HPV-ST led to the largest reduction in lifetime 
risk of cervical cancer, followed by HPV-VIA, and then 
VIA. Cancer risk reduction increased with the number of 
lifetime screens for all strategies. Screening every 5 years 
between ages 30 and 50 years reduced cancer risk by 
42.8%, 26.1% and 24.2% for HPV-ST, HPV-VIA and VIA, 
respectively.
Cost-effectiveness
Results from cost-effectiveness analysis are presented 
in table 2 and figure 3. HPV-ST was the least costly and 
most effective strategy at all screening frequencies, domi-
nating HPV-VIA and VIA. The ICERs of HPV-ST once, 
three times and five times per lifetime were US$130 per 
YLS, US$240 per YLS and US$470 per YLS, respectively. 
Baseline value Sensitivity analysis
  VIA US$14.64 – 
  Cost per cryotherapy10 45 US$5.85 US$27.37
  Cost per colposcopy and biopsy11 US$52.25 – 
Treatment of cancer27 37 46
  Local US$627 US$2328
  Regional US$797 US$2332
  Distant US$797 US$3953
1x: screening at age 39; 3x: screening at ages 30, 40 and 50; 5x: screening at ages 30, 35, 40, 45 and 50. 
*Costs are described in greater detail in the technical online supplementary appendix.
†Programmatic costs include costs for a programme assistant and a community preparedness campaign.
‡As CIN1 is not actually a health state in the model, colposcopy performance is based on the health state of no lesion, HPV infection, CIN2 or 
CIN3. A treatment threshold for CIN1 was estimated by weighting colposcopy sensitivity for HPV+ women based on the prevalence of CIN1 
among HPV+ women in the Uganda START-UP study.
§Base case direct medical costs of HPV testing and cryotherapy were informed by START-UP10 45 due to the ASPIRE trial using HPV 
genotyping technology at an additional expense (this would not be performed in a non-research setting) and the number of assumptions 
required for cryotherapy cost amortisation.
ASPIRE, Advances in Screening and Prevention of Reproductive Cancers; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; 
VIA, visual inspection with acetic acid. 
Table 1 Continued 
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HPV-ST would therefore be very cost-effective based on a 
willingness to pay threshold of Uganda’s 2014 GDP per 
capita (US$730).14
sensitivity and scenario analysis
Results from sensitivity and scenario analyses are 
described in tables 3 and 4. The finding that the HPV-ST 
strategy was the most effective was robust as we varied 
VIA primary screening test performance, VIA triage 
test performance, cryotherapy eligibility, cryotherapy 
efficacy, telephone compliance, loss to follow-up for 
tertiary care centre visits, screening coverage, propor-
tion of women who return for cryotherapy after initially 
refusing, direct medical costs of HPV testing and VIA, 
Table 2 Base case results*
ICER (US$/YLS)
Relative cervical cancer risk 
reduction† 
Absolute lifetime cervical 
cancer risk
No screening – – 4.2% (3.8%–4.7%)
HPV-ST 1x 130 (110–150) 15.0% (13.3%–16.6%) 3.5% (3.2%–4.0%)
VIA 1x DOM 7.2% (6.3%–8.2%) 3.9% (3.5%–4.3%)
HPV-VIA 1x DOM 7.6% (6.7%–8.7%) 3.9% (3.5%–4.3%)
HPV-ST 3x 240 (210–280) 33.0% (30.6%–35.5%) 2.8% (2.4%–3.1%)
VIA 3x DOM 16.9% (15.4%–18.8%) 3.5% (3.1%–3.9%)
HPV-VIA 3x DOM 18.4% (16.7%–20.5%) 3.4% (3.0%–3.8%)
HPV-ST 5x 470 (410–550) 42.8% (39.8%–45.6%) 2.4% (2.1%–2.7%)
VIA 5x DOM 24.2% (22.0%–26.4%) 3.2% (2.8%–3.5%)
HPV-VIA 5x DOM 26.1% (23.9%–28.5%) 3.1% (2.7%–3.4%)
The base case analysis compares all three screening strategies at all three screening frequencies. 1x: screening at age 39 years; 
3x=screening at ages 30, 40 and 50 years; 5x=screening at ages 30, 35, 40, 45 and 50 years; DOM: more costly and less effective or having a 
higher ICER than equally or more effective strategies; ICER: expressed in 2014 US$ per YLS.
*Values indicate the mean results across the top 50 best fitting parameter sets. The minimum and maximum values across these 50 
parameter sets are shown in parentheses.
†Relative reduction in lifetime risk of cervical cancer is compared with no screening.
DOM, dominated strategy; HPV, human papillomavirus; HPV-ST, community-based HPV self-collection with clinic-based cryotherapy of 
eligible HPV+ women; HPV-VIA, community-based HPV self-collection with clinic-based VIA triage and immediate treatment of eligible VIA+ 
women; ICER, incremental cost- effectiveness ratio; ST, screen-and-treat strategy; VIA, visual inspection with acetic acid; VIA, clinic-based 
VIA with immediate treatment of eligible VIA+ women; YLS, years of life saved.
Figure 3 Cost-effectiveness results: base case analysis. ICERs (expressed in 2014 US$ per year of life saved) are in 
parentheses for non-dominated strategies. 1x: screening at age 39 tears (yellow); 3x: screening at ages 30, 40 and 50 years 
(green); 5x: screening at ages 30, 35, 40, 45 and 50 years (orange); HPV-ST: HPV screen and treat (diamonds); HPV-VIA: HPV 
with VIA triage (squares); VIA: VIA screen and treat (triangles). The black line denotes the efficiency frontier. Any strategy lying 
to the right of the efficiency frontier is a dominated strategy because it is more costly and less effective or has a higher ICER 
than equally or more effective strategies. ICER, incremental cost-effectiveness ratio; ST, screen-and-treat strategy; VIA, visual 
inspection with acetic acid; YLS, year of life saved.
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Table 3 Results: sensitivity analyses, once in a lifetime screening*
Variables 
Relative reduction in 
lifetime cervical cancer risk ICER (US$/YLS)
Sensitivity analysis HPV-VIA HPV-ST VIA HPV-VIA HPV-ST VIA 
VIA performance  
(screening and  
triage test)31
41.4%/94.5% 3.9% 15.0% 3.7% DOM $130 DOM
VIA performance (triage test only)32 33 81.9%/66.6% 8.3% 15.0% 7.2% DOM $130 DOM
36.4%/90.4% 3.6% 15.0% 7.2% DOM $130 DOM
Cryotherapy eligibility (no lesion/CIN2
/CIN3/cancer)11 34–36
72.2%/58.1%/
58.1%/10.0%
7.1% 13.3% 6.9% DOM $160 DOM
79.6%/42.2%/
42.2%/10.0%
7.2% 13.2% 6.8% DOM $160 DOM
92.7%/87.7%/
82.7%/10.0%
7.6% 15.2% 7.2% DOM $130 DOM
79.8%/74.8%/
69.8%/10.0%
7.5% 14.4% 7.1% DOM $150 DOM
HPV test cost US$28.03 7.6% 15.0% 7.2% DOM $310 $300
Cryotherapy costs US$27.37 7.6% 15.0% 7.2% DOM $160 DOM
Cancer costs (local/regional/distant)37 US$2327
/US$2331/
US$3952
7.6% 15.0% 7.2% DOM $50 DOM
Direct medical costs (HPV/VIA) US$13.98/US$13.40
US$12.73/US$9.66
US$13.98/US$8.42
7.6%
7.6%
7.6%
15.0%
15.0%
15.0%
7.2%
7.2%
7.2%
DOM
DOM
DOM
$150
$130
$150
DOM
DOM
DOM
Cryotherapy effectiveness38 92% 8.7% 17.0% 8.1% DOM $120 DOM
70% 6.6% 12.8% 6.1% DOM $160 DOM
Proportion of women successfully 
contacted  
over phone with HPV test results
46.6% 5.6% 11.0% 7.2% DOM $190 DOM
75.0% 9.1% 17.8% 7.2% DOM $110 DOM
90.0% 11.0% 21.5% 7.2% DOM $90 DOM
Loss to follow-up‡ 0% 7.9% 15.5% 7.5% DOM $130 DOM
40% 7.2% 14.4% 6.8% DOM $150 DOM
Screening coverage 100% 10.9% 21.6% 10.2% DOM $130 DOM
85% 9.3% 18.3% 8.7% DOM $130 DOM
55% 6.0% 11.7% 5.6% DOM $130 DOM
40% 4.4% 8.6% 4.1% DOM $130 DOM
HPV test  
performance (sensitivity/specificity)
100%/100% to detect 
hrHPV
8.7% 17.3% 7.2% DOM $120 DOM
Cryotherapy compliance37† 52% 8.5% – 8.1% $250 – DOM
Colposcopy transport  
cost
US$0.50 7.6% 15.0% 7.2% DOM $140 DOM
Discount rate 0% 7.6% 15.0% 7.2% DOM $50 DOM
5% 7.6% 15.0% 7.2% DOM $230 DOM
Scenario—CHWs to  
reduce LTFU to  
women attending clinic for 
VIA or cryotherapy40
– 10.4% 20.3% 11.6% DOM $110 DOM
Scenario—100% LEEP following 
histological confirmation
– 7.8% 15.3% 7.4% DOM $140 DOM
Relative reduction in lifetime cancer risk is relative to no screening; incremental cost-effectiveness ratios are presented in 2014 US$; DOM: 
more costly or higher ICER than equally or more effective strategies. 
*Sensitivity analyses are described in detail in the technical online supplementary appendix.
†The model was not equipped to handle a change in this variable in the HPV-ST arm.
‡This variable refers only to loss to follow up for visits to the referral centre for colposcopy or follow-up of cryotherapy ineligible lesions. 
CHW, community health worker; CIN2, cervical intraepithelial neoplasia grade 2; DOM, dominated strategy; ICER, incremental cost-
effectiveness ratio; LEEP, loop electrosurgical excisional procedure; LTFU, loss to follow-up; ST, screen-and-treat strategy; VIA, visual 
inspection with acetic acid; YLS; year of life saved. 
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and discount rates. HPV-VIA was more effective than 
VIA in all sensitivity analyses conducted except when 
telephone contact rates of HPV-positive women were 
reduced to 46.6% in the HPV-VIA strategy or the sensi-
tivity of the VIA triage test was 36.4%. The effectiveness 
of different strategies was most sensitive to changes 
in screening coverage and compliance variables. For 
example, increasing screening coverage to 100% led to 
an increase in the relative reduction of lifetime cervical 
cancer risk from 15.0% to 21.6% (HPV-ST), while 
increasing telephone contact rates to 90% increased 
relative reduction of lifetime cervical cancer risk from 
15.0% to 21.5% (HPV-ST).
The HPV-ST strategy was very cost-effective and domi-
nated HPV-VIA and VIA in all sensitivity analyses, except 
when HPV test costs were more than quadrupled, in 
which case VIA was no longer a dominated strategy and 
had an ICER of US$300 per YLS. The ICER for HPV-ST 
fell below US$50 per YLS when cancer costs increased 
more than threefold and when there was no discounting 
of future costs and life years, and only increased above 
US$200 per YLS when HPV test costs increased or the 
discount rate was 5% (base case: US$130 per YLS). 
Scenario analyses demonstrated that using CHWs 
for in-person follow-up could be a very cost-effective 
approach to increase retention to screening pathways, 
while using LEEP instead of cryotherapy had little 
impact on both cancer reductions and ICERs compared 
with the base case.
When we assumed only HPV-VIA and VIA were avail-
able (table 4), as in the ASPIRE study, HPV-VIA domi-
nated VIA at all screening frequencies and would be 
very cost-effective with an ICER of US$570/YLS when 
performed five times per lifetime.
Patient and public involvement
There was no patient or public involvement in this study 
as it was based on mathematical modelling. However, 
the ASPIRE trial held multiple community engagement 
and education workshops to describe the interventions 
and provide broader education about HPV and cervical 
cancer in Uganda. The CHWs who were hired in the trial 
were members of the local community and were trained 
on the trial protocol and procedures. While all individual 
screening results were communicated with trial partici-
pants, there was no formal process for relaying the trial 
results to the participants. Trial results were disseminated 
to the local study team.
DIsCussIOn
We evaluated the cost-effectiveness of a novel self-col-
lected HPV testing strategy using uptake, follow-up and 
cost data from the ASPIRE trial in Uganda. To our knowl-
edge, this is the first study to use trial data to evaluate the 
cost-effectiveness of a delivery model relying on CHWs 
to offer home-based HPV self-collection. We found that 
screening with self-collected HPV testing followed by 
cryotherapy for eligible HPV-positive women (HPV-ST) 
Table 4 Sensitivity analysis: cost-effectiveness of HPV-VIA versus VIA*
Discounted cost per 
woman
Discounted life 
expectancy† (years) ICER (US$/YLS)
Relative cervical 
cancer risk 
reduction (%)
Absolute 
lifetime 
cervical cancer 
risk (%)
No screening US$9.19 (8.14–10.45) 26.2445 (26.2134–26.2737) – – 4.2 (3.8–4.7)
VIA 1x US$13.88 (12.84–
15.06)
26.2602 (26.2315–26.2883) DOM 7.2 (6.3–8.2) 3.9 (3.5–4.3)
HPV-VIA 1x US$13.99 (12.90–
15.12)
26.2618 (26.2334–26.2898) 280 (230–320) 7.6 (6.7–8.7) 3.9 (3.5–4.3)
VIA 3x US$23.77 (22.77–
24.83)
26.2827 (26.2575–26.3086) DOM 16.9 (15.4–18.8) 3.5 (3.1–3.9)
HPV-VIA 3x US$23.94 (22.84–
25.10)
26.2860 (26.2612–26.3117) 410 (360–480) 18.4 (16.7–20.5) 3.4 (3.0–3.8)
VIA 5x US$33.52 (32.58–
34.49)
26.2993 (26.2763–26.3235) DOM 24.2 (22.0–26.4) 3.2 (2.8–3.5)
HPV-VIA 5x US$33.85 (32.72–
34.85)
26.3033 (26.2812–26.3272) 570 (490–640) 26.1 (23.9–28.5) 3.1 (2.7–3.4)
1x: screening at age 39 years; 3x: screening at ages 30, 40 and 50 years; 5x: screening at ages 30, 35, 40, 45 and 50 years; HPV-VIA: HPV 
with VIA triage; VIA: VIA screen and treat. DOM: more costly or higher ICER than equally or more effective strategies; incremental cost-
effectiveness ratio (ICER): expressed in 2014 US$ per year of life saved (YLS); relative cancer reduction is the lifetime reduction relative to no 
screening.
*Values indicate the mean results across the top 50 top-fitting parameter sets. The minimum and maximum values across these 50 parameter 
sets are shown in parentheses.
†Discounted life expectancy is after age 9, the age at which women enter the model.
DOM, dominated strategy; ICER, incremental cost- effectiveness ratio; VIA, visual inspection with acetic acid; YLS, year of life saved. 
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would be very cost-effective in Uganda and could reduce 
the risk of cervical cancer by 15.0% if offered once in a 
lifetime at age 39 or up to 42.8% if offered every 5 years 
between ages 30 and 50 years. HPV testing with VIA triage 
of HPV-positive women to determine treatment and 
VIA alone were both more costly and less effective than 
HPV-ST, and thus not efficient strategies.
Previous cost-effectiveness studies evaluating self-col-
lected HPV testing have demonstrated that self-collection 
can be a cost-effective screening method if it achieves 
higher levels of population coverage than provider-col-
lected HPV testing.4 For instance, in weighing the 
trade-off between test sensitivity and higher screening 
coverage, Campos et al found that a 20% loss in test sensi-
tivity due to self-collection can be offset by a 20% gain 
in screening coverage.8 While the ASPIRE trial compared 
HPV self-collection to VIA, the results still demonstrate 
the importance of uptake rates in determining cost-effec-
tiveness. In the ASPIRE trial, 248 out of 250 women agreed 
to self-collect, while 121 out of 250 women attended the 
clinic for VIA. This enhanced uptake of HPV self-collec-
tion, when combined with the higher sensitivity to detect 
precancer of self-collected HPV testing (compared with 
VIA), rendered the HPV-ST screening strategy the most 
effective and cost-effective screening strategy in this anal-
ysis. These findings provide evidence that real-world 
increases in screening coverage due to door-to-door 
self-collection opportunities may translate into improved 
health and cost-effectiveness outcomes, and were robust 
to numerous sensitivity analyses.
The ASPIRE self-collection strategy could be further 
improved on if more HPV-positive women were success-
fully contacted with their results. In the ASPIRE trial, with 
a protocol of three phone attempts to contact women 
with their results, 34 of the 54 women who were HPV-pos-
itive could not be contacted. Of the HPV-positive women 
who were successfully contacted, 33 out of the 34 came 
in to Kisenyi clinic for follow-up. Strategies to improve 
delivery of test results should be explored. Sensitivity 
analysis showed that increasing delivery of results would 
further decrease cancer risk, and that having CHWs do 
in-person follow-up could be a cost-effective strategy to 
improve management for screen-positive women.40 Alter-
natively, other models of community-based self-collection 
have been proposed. Campos et al showed how a commu-
nity mobilisation campaign with group self-collection 
is a cost-effective alternative to provider collection if it 
increases population coverage.9 Future research should 
compare different models of offering self-collection and 
consider setting-specific factors that could make certain 
delivery methods more efficient.
An important finding is that HPV testing is more effec-
tive when there is no VIA triage before cryotherapy, 
a result that contradicts current WHO recommenda-
tions for countries with enough resources to provide a 
sequence of tests.5 This is due to the high false negative 
rate of VIA, the implications of which are amplified when 
the false negatives are in a high-risk group (ie, women 
already known to be HPV-positive). Our base case analysis 
assumed that VIA as a triage test performed similarly to 
VIA in a general screening population, detecting 73.6% of 
CIN2+.6 Other studies in Africa looking at VIA sensitivity 
as a triage test have showed large variability, with sensi-
tivities ranging from 25.0% to 81.9%.32 41 These findings 
suggest that future programmes should consider incorpo-
rating HPV-ST. However, this will lead to an increase in the 
number of cryotherapy procedures in women who may 
not have or may not develop precancer. While our results 
demonstrated that ST would be cost-effective, LMICs will 
likely face human resource and capacity constraints and 
may be overburdened by the high number of cryotherapy 
procedures. Moreover, while cryotherapy has been shown 
to be safe and acceptable,38 concern has arisen that there 
could be an increased risk of HIV incidence following 
cryotherapy.42 This is of particular concern in settings 
with high HIV prevalence. Better triage tests are needed 
to improve identification of women at high risk of devel-
oping cervical cancer while reducing the number of treat-
ments that are required of overburdened health systems.
Several limitations of this study should be noted. Our 
costing of the ASPIRE trial was hindered by the fact that 
the trial was not initially designed to evaluate cost-ef-
fectiveness, and thus all cost estimates are retrospec-
tive. Therefore, the trial may not reflect real-world (as 
opposed to study) conditions, and thus the amount paid 
for equipment, supplies and labour does not necessarily 
reflect actual programmatic costs. Cancer treatment costs 
had to be inferred from other studies. In a few cases, we 
used cost data from the PATH START-UP demonstration 
project to more accurately reflect real-world costs, as 
detailed in the technical online supplementary appendix. 
The base case assumption that VIA was more costly than 
HPV testing is unusual, and attributable to VIA having a 
provider cost (where HPV testing was self-collected) and 
requiring more CHW time to encourage compliance. 
Still, sensitivity analyses revealed that HPV-ST remained 
the dominant screening strategy even as the relative 
cost of HPV testing versus VIA was varied considerably. 
Concern has been raised that using GDP per capita as a 
threshold for cost-effectiveness may not be affordable in 
LMICs, however, even with a threshold of 50% of GDP per 
capita our analysis shows that HPV-ST one and three times 
per lifetime would be very cost-effective.43 Furthermore, 
the costing for this study was based on a trial involving 
250 women in each arm, which may not be sufficient to 
capture programmatic economies of scale.
In addition to limitations on costing data, the trial 
setting limited the scope of this cost-effectiveness analysis. 
It is unclear how real-world human resource constraints 
might affect the cost-effectiveness of the different 
screening strategies through impact on women’s waiting 
time in typical primary care settings. Furthermore, deci-
sion-makers will need to assess where limited healthcare 
provider time is best spent. It is of note that all the women 
in this study had access to a mobile phone. This may not 
be the case in rural and remote areas of Uganda, so novel 
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screening approaches may need to be developed that 
would be more suitable for these locations.
While it was not a stated objective of this study to eval-
uate the cost-effectiveness of NGCT screening, this was 
an integral part of the ASPIRE trial due to the hypoth-
esis that efficiency gains could be achieved by bundling 
health interventions with overlapping infrastructure 
needs. Moving forward, developing models that can eval-
uate the integrated delivery of primary care services will 
be critical to assess the wider impacts of new healthcare 
delivery methods in low-resource settings, as well as to 
capture potential synergies associated with packaging 
interventions.
In 2012, over 230 000 women in LMICs died from 
cervical cancer, approximately 2200 of whom were from 
Uganda.2 This study demonstrates that there are very 
cost-effective options that could significantly reduce 
morbidity and mortality attributable to cervical cancer. 
Implementation studies on a larger scale—that would 
assess the effectiveness and cost-effectiveness of commu-
nity-based screening in the context of the Ugandan 
health system—are warranted. Such studies will provide 
lessons for nascent screening programmes in low-re-
source settings with a high burden of cervical cancer.
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